Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Next Previous
Trial Profile

A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cerepetide (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Therapeutic Use
  • Acronyms ASCEND

Most Recent Events

  • 07 Aug 2025 According to a Lisata Therapeutics media release, final data and key findings from both cohorts of the ASCEND study are anticipated to be available later this year.
  • 07 Aug 2025 According to a Lisata Therapeutics media release, preliminary data from this trial were presented at the ESMO Gastrointestinal Cancers (ESMO-GI) Congress on July 2, 2025.
  • 26 Jun 2025 According to a Lisata Therapeutics media release, positive preliminary Cohort B data from this study will be presented at at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain, on 2 July, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top